IGC Pharma, Inc. (IGC)
NYSEAMERICAN: IGC · Real-Time Price · USD
0.2630
+0.0011 (0.42%)
Jun 26, 2026, 4:00 PM EDT - Market closed
IGC Pharma Revenue
IGC Pharma had revenue of $191.00K in the quarter ending September 30, 2025, a decrease of -53.64%. This brings the company's revenue in the last twelve months to $1.11M, down -6.51% year-over-year. In the fiscal year ending March 31, 2025, IGC Pharma had annual revenue of $1.27M, down -5.50%.
Revenue (ttm)
$1.11M
Revenue Growth
-6.51%
P/S Ratio
23.80
Revenue / Employee
$15,800
Employees
70
Market Cap
26.32M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 1.27M | -74.00K | -5.50% |
| Mar 31, 2024 | 1.35M | 434.00K | 47.64% |
| Mar 31, 2023 | 911.00K | 514.00K | 129.47% |
| Mar 31, 2022 | 397.00K | -501.00K | -55.79% |
| Mar 31, 2021 | 898.00K | -3.17M | -77.95% |
| Mar 31, 2020 | 4.07M | -1.04M | -20.41% |
| Mar 31, 2019 | 5.12M | 2.92M | 133.29% |
| Mar 31, 2018 | 2.19M | 1.61M | 277.86% |
| Mar 31, 2017 | 580.37K | -5.79M | -90.88% |
| Mar 31, 2016 | 6.37M | -1.31M | -17.11% |
| Mar 31, 2015 | 7.68M | 5.41M | 237.87% |
| Mar 31, 2014 | 2.27M | -5.76M | -71.69% |
| Mar 31, 2013 | 8.03M | 3.83M | 91.21% |
| Mar 31, 2012 | 4.20M | 125.63K | 3.08% |
| Mar 31, 2011 | 4.07M | -13.82M | -77.24% |
| Mar 31, 2010 | 17.90M | -17.44M | -49.35% |
| Mar 31, 2009 | 35.34M | 33.15M | 1,515.10% |
| Mar 31, 2008 | 2.19M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Barinthus Biotherapeutics | 14.97M |
| Evaxion | 7.53M |
| Kyntra Bio | 7.44M |
| Plus Therapeutics | 5.18M |
| Dyadic International | 3.81M |
| Vistagen Therapeutics | 1.27M |
| Serina Therapeutics | 130.00K |
IGC News
- 3 days ago - IGC Pharma announced beta version of Agentic Harmonization Assistant - TheFly
- 3 days ago - IGC Pharma's AHA Agentic AI Platform Reduces Alzheimer's Data Harmonization Time by 90% in Representative Workflow - Accesswire
- 15 days ago - IGC Pharma reaches 146-patient enrollment target for Phase 2 Calma trial - TheFly
- 15 days ago - IGC Pharma Reaches Previously Disclosed 146-Patient Enrollment Target in Phase 2 CALMA Trial, Advancing Toward Topline Analysis - Accesswire
- 17 days ago - Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.50, Citing Clinical Progress and 2026 Catalysts - Accesswire
- 24 days ago - IGC Pharma adds Mount Sinai clinical site as CALMA trial advances - TheFly
- 24 days ago - IGC Pharma Adds Mount Sinai Clinical Site as CALMA Trial Advances Toward Completion and Topline Analysis - Accesswire
- 5 weeks ago - IGC Pharma Reports First Quarter 2026 Financial Results with CALMA Phase 2 in the final stage, with 80% Enrollment - Accesswire